Primary Myelofibrosis (PMF)Phase 1NCT00910728

Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases

A Phase 1 study testing AZD1480 in people with Primary Myelofibrosis (PMF) and Post-Polycythaemia Vera, run by AstraZeneca at 3 sites in 2 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

Who is it for?: Ages 25 to 99 years
Conditions the study is for: Primary Myelofibrosis (PMF), Post-Polycythaemia Vera, Essential Thrombocythaemia Myelofibrosis
What is being tested?: AZD1480
Type of treatment: Pill or oral medicine
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 65 participants
Where: 3 sitesin 2 countries
Study dates: May 2009to Aug 2014
Phase: Phase 1
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 25 to 99 years
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

Patients with myelofibrosis requiring therapy
Evidence of post-menopausal status or sterile
ECOG Performance Status </=2

Who cannot join

Prior therapy with any JAK2 medications
Significant lung disorder or lung disease
Previous radiation therapy to chest wall or chest infection requiring antibiotic treatment within 28 days before study screening
Eye disease of the cornea
Patients requiring oxygen supplementation
Ejection fraction <45% (ECHO/MUGA) or significant pulmonary hypertension >40 mm Hg (by Echo/Doppler)

Show all 9Show fewer

Forced Expiratory Volume (FEV1)/Forced Vital Capacity (FVC) <70% predicted or >130% predicted
Diffusing capacity of the Lung for Carbon Monoxide (DLCO) corrected for hemoglobin <60% predicted, oxygen saturation <88% at rest or after a 6-minute flat walk, without supplemental oxygen
Chest infection requiring antibiotics within 7 days of the first dose of Investigational product.

Trial locations and contacts

3 sites in 2 countries.

Country

City, postcode or hospital

3 sites in 2 countries

United States2 sites

Research Site
Houston, Texas
Research Site
New York, New York

Other trials in United States

France1 site

Research Site
Villejuif

Other trials in France

About this study

Official title: A PhaseI/II, Open Label Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the JAK2 Inhibitor AZD1480 Administered Orally to Patients With Primary Myelofibrosis (PMF) and Post-Polycythaemia Vera/Essential Thrombocythaemia Myelofibrosis (Post-PV/ET MF

This study is being conducted to test study drug AZD1480 to see how it may work to treat myeloproliferative diseases. The main purpose of this study is to determine the safety and tolerability of AZD1480. This is the first time the drug has been given to humans and is classed as a first time in man study. Its main purpose is to establish a safe dosage of the drug and provide additional information on any potential side effects this drug may cause. The study will also assess the blood levels and action of AZD1480 in the body over a period of time and will indicate whether the drug has a therapeutic effect on myeloproliferative diseases.

Conditions: Primary Myelofibrosis (PMF), Post-Polycythaemia Vera, Essential Thrombocythaemia Myelofibrosis
Being tested: AZD1480
Keywords: Primary Myelofibrosis (PMF), Post-Polycythaemia Vera/Essential Thrombocythaemia Myelofibrosis (Post-PV/ET MF), Myeloproliferative diseases, Phase I, Phase II, Bone marrow
Medical subject headings: Primary Myelofibrosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

AZD1480Drug
Oral capsule 2.5 mg, 10 mg and 40 mg

Study groups in NCT00910728
Study group	Role	What they receive
1	Experimental	AZD1480 Receives: Drug: AZD1480

What is being measured

The primary outcome is the main question the study is designed to answer.

Pharmacokinetic Parameters Following Single Dosing: AUC0-12
Single dose AUC0-12 (ug*h/L)
Measured: 0 to 12 hour sampling (Day 1: 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours post dose)
Pharmacokinetic Parameters Following Single Dosing: AUC0-24
Single dose AUC0-24 (ug*h/L)
Measured: 0 to 24 hour sampling (Day 1: 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post dose)
Pharmacokinetic Parameters Following Single Dosing:AUC0-inf
Single dose AUC(0 to infinity) (ug*h/L)
Measured: 0 to 24 hour sampling (Day 1: 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post dose)
Pharmacokinetic Parameters Following Multiple Dosing: Cmax,ss
Multiple dose Cmax,ss (ug/L)
Measured: On Days 1 and 28 at 0, 0,5, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post dose, and at 0, 2, 4 hours post dose on Days 4 and 10
Pharmacokinetic Parameters Following Multiple Dosing: Cmin,ss
Multiple dose Cmin,ss (ug/L)
Measured: On Days 1 and 28 at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose and at 0, 2, 4 hours post-dose on Days 4 and 10.
Pharmacokinetic Parameters Following Single Dosing: Cmax
Single dose Cmax (ug/L)
Measured: 0 to 24 hour sampling (Day 1: 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post dose)
Pharmacokinetic Parameters Following Single Dosing: Vz/F
Single dose Vz/F (L)
Measured: 0 to 24 hour sampling (Day 1: 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post dose)
Pharmacokinetic Parameters Following Single Dosing: CL/F
Single dose CL/F (L/h)
Measured: 0 to 24 hour sampling (Day 1: 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post dose)
Pharmacokinetic Parameters Following Multiple Dosing: CLss/F
Multiple dose CLss/F (L/h)
Measured: On Days 1 and 28 at 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 hours post dose and at 0, 2, 4 hours post-dose
Pharamcokinetic Parameters Following Single Dosing: Tmax
Single dose Tmax (h)
Measured: 0 to 24 hour sampling (Day 1: 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post dose)
Pharamcokinetic Parameters Following Multiple Dosing: Tmax,ss
Multiple dose Tmax,ss (h)
Measured: On Days 1 and 28 at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post dose and at 0, 2, 4 hours post-dose on Days 4 and 10
Inhibition of PSTAT3 (Count)
PSTAT3 inhinition
Measured: 2hrs and 4 hrs post dose

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

May 2009Aug 2014

First posted1 Jun 2009 (estimated)
Study startMay 2009
Primary completionMar 2012
Study completionAug 2014

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Other trials for Primary Myelofibrosis (PMF)Studies of the same condition, open and under way.
More trials run by AstraZenecaThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 1
Primary purpose: Other
Allocation: Not applicable
Intervention model: Single group
Masking: None (open label)
Enrolment: 65 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT00910728
Sponsor's protocol ID: D1060C00001
Status last verified: Mar 2017
First submitted: 28 May 2009
Last updated: 24 Apr 2017
Results posted: Yes, on ClinicalTrials.gov
Data monitoring committee: No

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

RecruitingPhase 3
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF)
Not yet recruitingPhase 1
Maintenance Treatment With Imetelstat in Patients With High-Risk Myeloid Neoplasms After Allo-SCT
High-risk Myeloid Malignancy, Allogenic Stem Cell Transplantation
Not yet recruiting
Peri-Transplant Gecacitinib in Patients With Myelofibrosis Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Myelofibrosis, Primary Myelofibrosis (PMF)
RecruitingPhase 1
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Polycythemia Vera (PV), Myelofibrosis (MF)
Active, not recruitingPhase 2
Extended Access of Momelotinib in Adults With Myelofibrosis
Primary Myelofibrosis

All Primary Myelofibrosis (PMF) trials

Study at a glance

From the registry record, last updated by the sponsor on 24 Apr 2017. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: A PhaseI/II, Open Label Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the JAK2 Inhibitor AZD1480 Administered Orally to Patients With Primary Myelofibrosis (PMF) and Post-Polycythaemia Vera/Essential Thrombocythaemia Myelofibrosis (Post-PV/ET MF
ClinicalTrials.gov ID: NCT00910728
Acronym / sponsor ID: D1060C00001
Conditions: Primary Myelofibrosis (PMF), Post-Polycythaemia Vera, Essential Thrombocythaemia Myelofibrosis
Keywords: Primary Myelofibrosis (PMF), Post-Polycythaemia Vera/Essential Thrombocythaemia Myelofibrosis (Post-PV/ET MF), Myeloproliferative diseases, Phase I, Phase II, Bone marrow
Phase: Phase 1
Study type: Interventional
Recruitment status: Completed
Enrolment: 65 participants (actual)
Lead sponsor: AstraZenecaIndustry (pharma, biotech, devices)
Collaborators: University of Texas, New York City Hoffman Center, Gustave Roussy, Cancer Campus, Grand Paris
Study start: May 2009
Primary completion: Mar 2012 (actual)
Study completion: Aug 2014 (actual)
First posted: 1 Jun 2009 (estimated)
Results: Posted 24 Apr 2017

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Study design

Primary purpose: Other
Allocation: Not applicable
Intervention model: Single group
Masking: None (open label)
Number of arms: 1

Arm	Type	Receives
1	Experimental	Drug: AZD1480AZD1480

Who may qualify

Ages: 25 to 99 years
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (3 listed)

Patients with myelofibrosis requiring therapy
Evidence of post-menopausal status or sterile
ECOG Performance Status </=2

Key exclusion criteria (9 listed)

Prior therapy with any JAK2 medications
Significant lung disorder or lung disease
Previous radiation therapy to chest wall or chest infection requiring antibiotic treatment within 28 days before study screening
Eye disease of the cornea
Patients requiring oxygen supplementation

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
AZD1480Oral capsule 2.5 mg, 10 mg and 40 mg	Drug	1

Primary outcome

Pharmacokinetic Parameters Following Single Dosing: AUC0-12
Time frame: 0 to 12 hour sampling (Day 1: 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours post dose)
Single dose AUC0-12 (ug*h/L)
Pharmacokinetic Parameters Following Single Dosing: AUC0-24
Time frame: 0 to 24 hour sampling (Day 1: 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post dose)
Single dose AUC0-24 (ug*h/L)
Pharmacokinetic Parameters Following Single Dosing:AUC0-inf
Time frame: 0 to 24 hour sampling (Day 1: 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post dose)
Single dose AUC(0 to infinity) (ug*h/L)
Pharmacokinetic Parameters Following Multiple Dosing: Cmax,ss
Time frame: On Days 1 and 28 at 0, 0,5, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post dose, and at 0, 2, 4 hours post dose on Days 4 and 10
Multiple dose Cmax,ss (ug/L)
Pharmacokinetic Parameters Following Multiple Dosing: Cmin,ss
Time frame: On Days 1 and 28 at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose and at 0, 2, 4 hours post-dose on Days 4 and 10.
Multiple dose Cmin,ss (ug/L)
Pharmacokinetic Parameters Following Single Dosing: Cmax
Time frame: 0 to 24 hour sampling (Day 1: 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post dose)
Single dose Cmax (ug/L)
Pharmacokinetic Parameters Following Single Dosing: Vz/F
Time frame: 0 to 24 hour sampling (Day 1: 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post dose)
Single dose Vz/F (L)
Pharmacokinetic Parameters Following Single Dosing: CL/F
Time frame: 0 to 24 hour sampling (Day 1: 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post dose)
Single dose CL/F (L/h)
Pharmacokinetic Parameters Following Multiple Dosing: CLss/F
Time frame: On Days 1 and 28 at 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 hours post dose and at 0, 2, 4 hours post-dose
Multiple dose CLss/F (L/h)
Pharamcokinetic Parameters Following Single Dosing: Tmax
Time frame: 0 to 24 hour sampling (Day 1: 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post dose)
Single dose Tmax (h)
Pharamcokinetic Parameters Following Multiple Dosing: Tmax,ss
Time frame: On Days 1 and 28 at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post dose and at 0, 2, 4 hours post-dose on Days 4 and 10
Multiple dose Tmax,ss (h)
Inhibition of PSTAT3 (Count)
Time frame: 2hrs and 4 hrs post dose
PSTAT3 inhinition

Results and safety

Results posted to the registry on 24 Apr 2017, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
2.5 mg QD	6	0
5.0 mg QD	3	0
10 mg QD	3	0
30 mg QD	3	0
50 mg QD	6	1
70 mg QD	1	0
10 mg BID	6	0
15 mg BID	4	1
20 mg QD	3	0

Primary outcome: Pharmacokinetic Parameters Following Single Dosing: AUC0-12

Time frame: 0 to 12 hour sampling (Day 1: 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours post dose). Geometric mean (Standard Deviation). Unit: ug*h/L

Measure	2.5 mg QD n = 6	5.0 mg QD n = 3	10 mg QD n = 3	30 mg QD n = 3	70 mg QD n = 1	10 mg BID n = 6	15 mg BID n = 4	50 mg QD n = 6	20 mg QD n = 3
Value	69.2 (27.5)	295 (68.2)	278 (257)	1860 (546)	5800 (0)	425 (190)	497 (191)	3090 (2060)	472 (257)

Population analysed: Pharmacokinetic. Note - no GeoCV(%) was captured in the TFL. Hence the geometric mean was still presented as applicable but with the SD (since only available).

Primary outcome: Pharmacokinetic Parameters Following Single Dosing: AUC0-24

Time frame: 0 to 24 hour sampling (Day 1: 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post dose). Geometric mean (Standard Deviation). Unit: ug*h/L

Measure	2.5 mg QD n = 6	5.0 mg QD n = 3	10 mg QD n = 3	30 mg QD n = 3	70 mg QD n = 1	10 mg BID n = 0	15 mg BID n = 0	50 mg QD n = 6	20 mg QD n = 3
Value	70.2 (28.7)	308 (76)	285 (252)	2000 (624)	6260 (0)	–	–	3540 (2570)	508 (280)

Population analysed: Pharmacokinetic. Note - no GeoCV(%) was captured in the TFL. Hence the geometric mean was still presented as applicable but with the SD (since only available). From the BID schedule we can not derive the single dosing AUC0\_24 and hence this is not presented/calculated.

Primary outcome: Pharmacokinetic Parameters Following Single Dosing:AUC0-inf

Time frame: 0 to 24 hour sampling (Day 1: 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post dose). Geometric mean (Standard Deviation). Unit: ug*h/L

Measure	2.5 mg QD n = 6	5.0 mg QD n = 3	10 mg QD n = 3	30 mg QD n = 3	70 mg QD n = 1	10 mg BID n = 0	15 mg BID n = 0	50 mg QD n = 6	20 mg QD n = 3
Value	83.5 (36.6)	312 (79.5)	378 (290)	2040 (657)	6300 (0)	–	–	3650 (2980)	517 (294)

Population analysed: Pharmacokinetic. Note - no GeoCV(%) was captured in the TFL. Hence the geometric mean was still presented as applicable but with the SD (since only available). From the BID (twice a day dosing schedules) we can not derive the PK parameter AUC0\_inf following single dosing. With that these do not contribute.

Primary outcome: Pharmacokinetic Parameters Following Multiple Dosing: Cmax,ss

Time frame: On Days 1 and 28 at 0, 0,5, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post dose, and at 0, 2, 4 hours post dose on Days 4 and 10. Geometric mean (Standard Deviation). Unit: ug/L

Measure	2.5 mg QD n = 5	5.0 mg QD n = 3	10 mg QD n = 3	30 mg QD n = 3	70 mg QD n = 1	10 mg BID n = 5	15 mg BID n = 4	50 mg QD n = 5	20 mg QD n = 3
Value	51.3 (18)	134 (36.3)	176 (179)	658 (265)	1500 (0)	218 (72.3)	334 (68.2)	924 (461)	241 (346)

Population analysed: Pharmacokinetic. Note - no GeoCV(%) was captured in the TFL. Hence the geometric mean was still presented as applicable but with the SD (since only available).

Adverse events

Time frame: Throughout study continuously and 30 days post discontinuation of treatment. Other adverse events reported at 5% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
2.5 mg QD	2 of 6 (33.3%)	6 of 6 (100%)	Not reported
5.0 mg QD	2 of 3 (66.7%)	3 of 3 (100%)	Not reported
10 mg QD	0 of 3 (0%)	3 of 3 (100%)	Not reported
70 mg QD	0 of 1 (0%)	1 of 1 (100%)	Not reported
15 mg BID	1 of 4 (25%)	4 of 4 (100%)	Not reported
20 mg QD	3 of 3 (100%)	3 of 3 (100%)	Not reported
30 mg QD	0 of 3 (0%)	3 of 3 (100%)	Not reported
50 mg QD	4 of 6 (66.7%)	6 of 6 (100%)	Not reported
10 mg BID	3 of 6 (50%)	6 of 6 (100%)	Not reported

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 24 Apr 2017.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.

Related trials for Primary Myelofibrosis (PMF)

RecruitingPhase 3
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF)
Not yet recruitingPhase 1
Maintenance Treatment With Imetelstat in Patients With High-Risk Myeloid Neoplasms After Allo-SCT
High-risk Myeloid Malignancy, Allogenic Stem Cell Transplantation
Not yet recruiting
Peri-Transplant Gecacitinib in Patients With Myelofibrosis Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Myelofibrosis, Primary Myelofibrosis (PMF)
RecruitingPhase 1
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Polycythemia Vera (PV), Myelofibrosis (MF)
Active, not recruitingPhase 2
Extended Access of Momelotinib in Adults With Myelofibrosis
Primary Myelofibrosis

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Srdan Verstovsek, MD principal investigator

MDACC

Ronald Hoffman, MD principal investigator

Mt. Sinai

Vincent Ribrag, MD principal investigator

Gustave Roussy, Cancer Campus, Grand Paris

3 sites in 2 countries: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing AZD1480 in people with Primary Myelofibrosis (PMF) and Post-Polycythaemia Vera, run by AstraZeneca at 3 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 24 Apr 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in United States, France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 24 Apr 2017). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Pharmacokinetic Parameters Following Single Dosing: AUC0-12 (time frame: 0 to 12 hour sampling (Day 1: 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours post dose)). The study lists 12 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00910728.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Apr 2017.